Financial Survey: Covance (CVD) & Its Peers

Covance (NYSE: CVD) is one of 11 publicly-traded companies in the “Biotechnology & Medical Research – NEC” industry, but how does it weigh in compared to its rivals? We will compare Covance to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations.


This table compares Covance and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Covance 7.70% 12.64% 8.17%
Covance Competitors -54.10% -40.68% -19.92%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Covance and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Covance 0 0 0 0 N/A
Covance Competitors 11 113 294 1 2.68

As a group, “Biotechnology & Medical Research – NEC” companies have a potential upside of 231.07%. Given Covance’s rivals higher probable upside, analysts plainly believe Covance has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Covance and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Covance N/A N/A 33.05
Covance Competitors $3.18 million -$38.43 million -28.38

Covance’s rivals have higher revenue, but lower earnings than Covance. Covance is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

28.1% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by institutional investors. 21.9% of shares of all “Biotechnology & Medical Research – NEC” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

About Covance

Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Receive News & Ratings for Covance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit